Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | adrenocortical carcinoma |
| ICD-0-3 | NA |
| Methods | MSP-PCR, Cell proliferation assay etc. |
| Sample | pathological adrenal glands, cell line (NCI-H295R) |
| Expression Pattern | down-regulated |
| Function Description | In the adrenocortical carcinoma cell line NCI-H295R, abundant IGF-II, but minimal H19, RNA expression was detected by Northern blotting. Treatment with a cytosine methylation inhibitor, 5-aza-2'-deoxycytidine, increased H19 RNA expression, whereas it decreased IGF-II mRNA accumulation dose- and time-dependently and reduced cell proliferation to 10% in 7 d. Our results suggest that altered DNA methylation of the H19 promoter is involved in the abnormal expression of both H19 and IGF-II genes in human adrenocortical carcinomas. |
| Pubmed ID | 11889182 |
| Year | 2002 |
| Title | Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for adrenocortical carcinoma | OMIM COSMIC |